Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors as Phase 3 PAH Trial Advances
Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a Wilmington, Delaware-based clinical-stage pharmaceutical company, has appointed Scott M. Wasserman, MD, to its Board... Read More ...
Artificial intelligence in medicine is most often associated with detecting abnormalities in medical images, analyzing test ...
Sisram Medical Ltd. (1696.HK), a medical aesthetics company offering energy-based devices, injectables, and other solutions, announced that China's National Medical Products Administration (NMPA) has ...
October 19 proved to be an emotional rollercoaster for Taiwan’s biotechnology investors. Within hours, three major material ...
Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...
Nobel-winning scientific breakthroughs have repeatedly emerged from organisms once considered too simple or too distant from human biology to be useful. Research on yeast revealed fundamental ...
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the ...
Germany is the European Union’s (EU) largest pharmaceutical market by revenue and has the highest medical biotechnology ...
Most recently, Dr. Weber was Chief Medical Officer of Auregen BioTherapeutics. There he led a Phase I/II trial under an FDA-cleared IND of an autologous, 3D-printed cartilage implant to repair ...
Sensorion jumped 13.6% to more than €7.1, welcomed for the appointment, effective Nov. 2, 2026, of Peter Weber as chief ...
Biotechnology company Sensorion SA (ALSEN.PA) on Monday announced the appointment of Peter Weber as chief medical officer, effective November 2, 2026. Weber, an Otologist and Neurotologist, previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results